Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines

European Journal of Pharmacology

Volumn 532, Issue 3, 2006, Pages 214-222

  Bernardi, Andressa ^a   Jacques Silva, Maria C ^a   Delgado Cañedo, Andrés ^a   Lenz, Guido ^a   Battastini, Ana M O ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

Author keywords

COX; Glioma; Indomethacin; NSAID; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CASPASE 3; CASPASE 7; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SULINDAC SULFIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; GLIOMA CELL; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; RAT; TUMOR CELL CULTURE;

ACETAMINOPHEN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; GLIOMA; HUMANS; INDOMETHACIN; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITROBENZENES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; SRC-FAMILY KINASES; SULFONAMIDES; TIME FACTORS;

EID: 33644543418     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.01.008     Document Type: Article

References (59)

1. S.A. Aaronson Growth factors and cancer Science 254 1991 1146 1153
2. N.G. Avgeropoulos, and T.T. Batchelor New strategies for malignant gliomas The Oncologist 4 1999 209 224
3. M.A. Bae, J.E. Pie, and B.J. Song Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH2-terminal protein kinase-related cell death pathway Mol. Pharmacol. 60 2001 547 556
4. J.S. Bae, M.K. Jang, S. Hong, W.G. An, Y.H. Choi, H.D. Kim, and J. Cheong Phosphorylation of NF-kappa B by calmodulin-dependent kinase IV activates anti-apoptotic gene expression Biochem. Biophys. Res. Commun. 13 305 2003 1094 1098
5. W.L. Biffl, R. Carnaggio, E.E. Moore, D.J. Ciesla, J.L. Johnson, and C.C. Silliman Clinically relevant hypertonicity prevents stored blood-and lipid-mediated delayed neutrophil apoptosis independent of p38 MAPK or caspase-3 activation Surgery 134 2003 86 91
6. J.D. Bjorge, D.J. Jakimiw, and D.J. Fujita Selected glimpses into the activation and function of Src kinase Oncogene 19 2000 5620 5635
7. A.A. Brandes, L.M. Pasetto, and S. Monfardini New drugs in recurrent high grade gliomas Anticancer Res. 20 2000 1913 1920
8. M. Bredel, and I.F. Pollack The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy Acta Neurochir. (Wien) 139 1997 1000 1013
9. M. Bredel, and I.F. Pollack The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas Brain Res. Rev. 29 1999 232 249
10. 2-vitamin D3 signalling to the nucleus in muscle cells Biochim. Biophys. Acta 1541 2001 179 187
11. W.A. Carvalho, R.D.S. Carvalho, and F. Rios-Santos Specific cyclooxygenase-2 inhibitor analgesics: therapeutic advances Rev. Bras. Anestesiol. 54 2004 448 464
12. D. Casper, R. Lekhraj, U.S. Yaparpalvi, A. Pidel, W.A. Jaggernauth, P. Werner, S. Tribius, J.D. Rowe, and P.A. LaSala Acetaminophen selectively reduces glioma cell growth and increases radiosensitivity in culture J. Neurooncol. 46 2000 215 229
13. D. Casper, U. Yaparpalvi, N. Rempel, and P. Werner Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro Neurosci. Lett. 11 289 2000 201 204
14. P.F. Coogan, L. Rosenberg, J.R. Palmer, B.L. Strom, A.G. Zauber, P.D. Stolley, and S. Shapiro Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel Cancer Epidemiol. Biomark. Prev. 9 2000 119 123
15. J.P. Courade, D. Besse, C. Delchambre, N. Hanoun, M. Hamon, A. Eschalier, F. Caussade, and A. Cloared Acetaminophen distribution in the rat central nervous system Life Sci. 69 2001 1455 1464
16. A.B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? The Oncologist 7 2002 17 33
17. M.H. Deininger, M. Weller, J. Streffer, M. Mittelbronn, and R. Meyermann Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo Acta Neuropathol. 98 1999 240 244
18. D.J.E. Elder, D.E. Halton, L.C. Playle, and C. Paraskeva The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells Int. J. Cancer 99 2002 323 327
19. Y. Eli, F. Przedeeki, G. Levin, N. Kariv, and A. Raz Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo Biochem. Pharmacol. 61 2001 565 571
20. E. Fosslien Review: molecular pathology of cyclooxygenase-2 in cancer induced angiogenesis Ann. Clin. Lab. Sci. 31 2001 325 348
21. Y. Fujiwara, A. Tarnawski, K. Fujiwara, T. Arakawa, and K. Kobayashi Inhibitory effects of indomethacin on growth and proliferation of gastric carcinoma cells KATO III J. Physiol. Pharmacol. 44 1993 147 153
22. N. Futaki, S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro Prostaglandins 47 1994 55 59
23. 7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells Am. J. Cell Physiol. Cell Phys. 284 2003 C571 C581
24. T.C. He, T.A. Chan, B. Volgelstein, and K.W. Kinzler PPAR-gamma is an APC-regulated target of nonsteroidal antiinflammatory drugs Cell 99 1999 335
25. T. Hida, Y. Yatabe, H. Achiwa, H. Muramatsu, K. Kozaki, S. Nakamura, M. Ogawa, T. Mitsudomi, T. Sugiura, and T. Takahashi Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas Cancer Res. 58 1998 3761 3764
26. E.C. Holland Gliomagenesis: genetic alterations and mouse models Nature 2 2001 120 129
27. L.R. Howe, K. Subbaramaiah, A.M.C. Brown, and A.J. Dannenberg Cyclooxygenase-2: a target for the prevention and treatment of breast cancer Endocr. -Relat. Cancer 8 2001 97 114
28. M.C. Jacques-Silva, R. Rodnight, G. Lenz, Z. Liao, Q. Kong, M. Tran, Y. Kang, F.A. Gonzales, G.A. Weisman, and J.T. Neary P2X7 receptors stimulate AKT phosphorylation in astrocytes Br. J. Pharmacol. 141 2004 1107 1118
29. T. Joki, O. Heese, D.C. Nikas, L. Bello, J. Zhang, S.K. Kraeft, N.T. Seyfried, T. Abe, L.B. Chen, R.S. Carroll, and P. Black The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J. Biol. Chem. 275 2000 11397 11403
30. T. Joki, R.S. Carroll, I.F. Dunn, J. Zhang, T. Abe, and P.M. Black Assessment of alterations in gene expression in recurrent malignant glioma after radiotherapy using complementary deoxyribonucleic acid microarrays Neurosurgery 48 2001 195 2001
31. A. Kardosh, M. Blumenthal, W.J. Wang, T.C. Chen, and A.H. Schonthal Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines Can. Biol. Ther. 3 2004 55 62
32. E.G. Lentjes, and C.A. van Ginneken Pharmacokinetics of flufenamic acid in man Int. J. Clin. Pharmacol. Ther. Toxicol. 25 1987 185 189
33. R. Meller, S.L. Skradski, R.P. Simon, and D.C. Henshall Expression, proteolysis and activation of caspases 6 and 7 during rat C6 glioma cell apoptosis Neurosci. Lett. 324 2002 33 36
34. J.T. Neary, Y. Kang, Y. Bu, B. Yu, K. Akong, and C.M. Peters Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: involvement of a calcium-independent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway J. Neurosci. 19 1999 4211 4220
35. Cas tyrosine phosphorylation requires calcium-dependent c-Src activation J. Biol. Chem. 274 1999 26803 26809
36. O. Ordan, R. Rotem, H. Jaspers, and E. Flescher Stress-responsive JNK mitogen-activated protein kinase mediates aspirin-induced suppression of B16 melanoma cellular proliferation Br. J. Pharmacol. 138 2003 1156 1162
37. W.R. Overton, and J.P. McCoy Jr. Reversing the effect of formalin on the binding of propidium iodide to DNA Cytometry 16 1994 351 356
38. B. Parashar, L.S. Shankar, K. O'Guin, J. Butler, B. Vikram, and B. Shafit-Zagardo Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective COX-2 inhibitor J. Neuro-Oncol. 71 2005 141 148
39. M.H. Pillinger, C. Capodici, P. Rosenthal, N. Kheterpal, S. Hanft, M.R. Philips, and G. Weissmann Modes of action of aspirin-like drugs: salicilates inhibit ERK activation and integrin-dependent neutrophil adhesion Proc. Natl. Acad. Sci. U. S. A. 95 1998 14540 14545
40. W.R. Ravis, C.J. Diskin, K.D. Campagna, C.R. Clark, and C.L. McMillian Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure J. Clin. Pharmacol. 33 1993 527 533
41. B. Rigas, and S.J. Shiff Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction Med. Hypothesis 54 2000 210 215
42. A. Ristimaki, A. Hunkanen, H. Jankala, P. Sipponen, and M. Harkonen Expression of cyclooxygenase-2 in human gastric carcinoma Cancer Res. 57 1997 1276 1280
43. A. Ristimaki, A. Sivula, J. Lundin, M. Lundin, T. Salminen, C. Haglund, H. Joensuu, and J. Isola Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Res. 62 2002 632 635
44. J. Schelegel, G. Piontek, B. Budde, F. Neff, and A. Kraus The Akt/PKB-dependent anti-apoptotic pathway and the MAPK cascade are alternatively activated in human glioblastoma multiforme Cancer Lett. 158 2000 103 108
45. P. Schwenger, D. Alpert, E.Y. Skolnick, and J. Vilcek Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation Mol. Cell. Biol. 18 1998 78 84
46. R. Seger, and E.G. Krebs The MAPK signaling cascade FASEB J. 9 1995 726 735
47. T. Shono, P.J. Tofilon, J.M. Bruner, O. Owolabi, and F.F. Lang Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations Cancer Res. 61 2001 4375 4381
48. W.L. Smith, R.M. Garavito, and D.L. DeWitt Prostaglandin endoperoxidase H synthases (cyclooxygenases)-1 and -2 J. Biol. Chem. 271 1996 33157 33160
49. W.L. Smith, D.L. DeWitt, and R.M. Garavito Cyclooxygenases: structural, cellular and molecular biology Annu. Rev. Biochem. 69 2000 145 182
50. I. Tegeder, J. Pfeilschifter, and G. Geisslinger Cyclooxygenase- independent actions of cyclooxygenase inhibitors FASEB J. 15 2001 2057 2072
51. R. Vadlamudi, M. Mandal, L. Adam, G. Steinbach, J. Mendelsonh, and R. Kumar Regulation of the cyclooxygenase pathway by the HER-2 receptor Oncogene 18 1999 305 314
52. + system Clin. Chim. Acta 24 1969 23 27
53. C.S. Williams, M. Mann, and R.N. DuBois The role of cyclooxygenases in inflammation, cancer and development Oncogene 18 1999 7908 7916
54. K.T. Wilson, S. Fu, K.S. Ramanujan, and S.J. Meltzer Increase expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res. 58 1998 2929 2934
55. W. Xie, and H.R. Herschmann Transcriptional regulation of prostaglandin synthase-2 gene expression by platelet derived growth factor and serum J. Biol. Chem. 271 1996 131742 131748
56. Y. Yamamoto, M.J. Yin, K.M. Lin, and R.B. Gaynor Sulindac inhibits activation of the NF-κB pathway J. Biol. Chem. 274 1999 27307 27314
57. H.M. Yang, K.W. Kim, H.J. You, S.I. Jeon, S.W. Youn, S.H. Kim, B.H. Oh, M.M. Lee, Y.B. Park, and K. Walsh Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of AKT signaling Circulation 110 3 2004 301 308
58. M. Xu, and G.Y. Zhang Effect of indomethacin on cell cycle proteins in colon cancer cell lines World J. Gastroenterol. 11911 2005 1692 1696
59. X. Zhang, S.G. Morhan, R. Langenbach, and D.A. Young Malignant transformation and antineoplasic actions of non steroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblast J. Exp. Med. 190 1999 451